Download pdf
Gene and peptide in the treatment of chlamydia trachomatis infections: beginning of an era?
- 1 Chongqing Yucai Secondary School, Chongqing, China
* Author to whom correspondence should be addressed.
Abstract
Chlamydia trachomatis leads to the most common sexually transmitted infection (STI) worldwide, resulting in short-term and long-term health issues. The treatments for chlamydia trachomatis infection are often a hot research direction. The efficiency of antibiotics, the conventional therapy for chlamydia trachomatis infection, is decreasing gradually because of resistance, especially azithromycin. Thus, it is necessary to find new therapies to treat chlamydia trachomatis infection with higher specificity and effectiveness. Among all the trials, gene and peptide therapy stand out. As for gene therapy, IRF5 and IL-10RA are related to macrophage-chlamydia interactions. Their roles are vital in order to cure chlamydia trachomatis infection. With regard to peptide therapy, pep-1, LL-37, and melittin showed outstanding abilities in inhibiting the growth of chlamydia trachomatis. However, multiple challenges for the development of these therapies remained. Deep researches are required to address these problems in order to put these treatments into clinical use. This review summarizes the conventional treatments, and introduces gene therapy and peptide therapy for chlamydia trachomatis infection.
Keywords
chlamydia trachomatis, peptide therapy., gene therapy
[1]. C. Deal, W. Cates, R. Peeling, and A. Wald, Emerg Infect Dis 10, e2 (2004).
[2]. F.R. Ochsendorf, C.R. Falk Ochsendorf, Z. Dermatologie Venerologie, and K.J. Goethe-, Andrologia 40, 72–75 (2008).
[3]. K. Manavi, Best Pract Res Clin Obstet Gynaecol 20, 941–951 (2006).
[4]. P.A. Mårdh, Best Pract Res Clin Obstet Gynaecol 16, 847–864 (2002).
[5]. J.C. Dombrowski, M.R. Wierzbicki, L.M. Newman, J.A. Powell, A. Miller, D. Dithmer, O.O. Soge, and K.H. Mayer, Clinical Infectious Diseases 73, 824–831 (2021).
[6]. V. Škerk, S. Schönwald, Z. Strapač, A. Beus, I. Francetić, I. Krhen, V. Lesko, and J. Vuković, Journal of Chemotherapy 13, 176–181 (2013).
[7]. F.Y.S. Kong, S.N. Tabrizi, M. Law, L.A. Vodstrcil, M. Chen, C.K. Fairley, R. Guy, C. Bradshaw, and J.S. Hocking, Clinical Infectious Diseases 59, 193–205 (2014).
[8]. L. Slaney, H. Chubb, A. Ronald, and R. Brunham, Journal of Antimicrobial Chemotherapy 25, 1–5 (1990).
[9]. N.S. Silverman, M. Sullivan, M. Hochman, M. Womack, and D.L. Jungkind, Am J Obstet Gynecol 170, 829–832 (1994).
[10]. M.R. Hammerschlag, J.W. Chandler, E.R. Alexander, M. English, W.-T. Chiang, L. Koutsky, D.A. Eschenbach, and J.R. Smith, JAMA 244, 2291–2293 (1980).
[11]. J. Schachter, R.L. Sweet, M. Grossman, D. Landers, M. Robbie, and E. Bishop, N Engl J Med 314, 276–279 (2009).
[12]. B.E. Batteiger, W. Tu, S. Ofner, B. van der Pol, D.R. Stothard, D.P. Orr, B.P. Katz, and J.D. Fortenberry, J Infect Dis 201, 42–51 (2010).
[13]. J. Somani, V.B. Bhullar, K.A. Workowski, C.E. Farshy, and C.M. Black, J Infect Dis 181, 1421–1427 (2000).
[14]. B.A. Bunnell and R.A. Morgan, Clin Microbiol Rev 11, 42–56 (1998).
[15]. A.T.Y. Yeung, C. Hale, A.H. Lee, E.E. Gill, W. Bushell, D. Parry-Smith, D. Goulding, D. Pickard, T. Roumeliotis, J. Choudhary, N. Thomson, W.C. Skarnes, G. Dougan, and R.E.W. Hancock, Nature Communications 2017 8:1 8, 1–12 (2017).
[16]. L. Wang, N. Wang, W. Zhang, X. Cheng, Z. Yan, G. Shao, X. Wang, R. Wang, and C. Fu, Signal Transduction and Targeted Therapy 2022 7:1 7, 1–27 (2022).
[17]. E.C.L. de Oliveira, K. Santana, L. Josino, A.H. Lima e Lima, and C. de Souza de Sales Júnior, Scientific Reports 2021 11:1 11, 1–15 (2021).
[18]. N. Park, K. Yamanaka, D. Tran, P. Chandrangsu, J.C. Akers, J.C. de Leon, N.S. Morrissette, M.E. Selsted, and M. Tan, Journal of Antimicrobial Chemotherapy 63, 115–123 (2009).
[19]. S. Dosler and E. Karaaslan, Peptides (N.Y.) 62, 32–37 (2014).
[20]. L. Tang, J. Chen, Z. Zhou, P. Yu, Z. Yang, and G. Zhong, Microbes Infect 17, 402–408 (2015).
[21]. V.N. Lazarev, T.M. Parfenova, S.K. Gularyan, O.Y. Misyurina, T.A. Akopian, and V.M. Govorun, Int J Antimicrob Agents 19, 133–137 (2002).
[22]. R.E.W. Hancock and H.G. Sahl, Nature Biotechnology 2006 24:12 24, 1551–1557 (2006).
Cite this article
Qin,J. (2023). Gene and peptide in the treatment of chlamydia trachomatis infections: beginning of an era?. Theoretical and Natural Science,4,18-25.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of the 2nd International Conference on Biological Engineering and Medical Science (ICBioMed 2022), Part II
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).